Crinetics Pharmaceuticals Inc
For the period ended Jun 30, 2024. Filed Aug 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 8, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
Checking your notes…
EXHIBIT INDEX
| Exhibit · Incorporated by Reference · Filed | ||||||
|---|---|---|---|---|---|---|
| Number | Exhibit Description | Form | File No. | Exhibit | Filing Date | Herewith |
| 3.1 | Amended and Restated Certificate of Incorporation | 8-K | 001-38583 | 3.3 | 7/20/2018 | |
| 3.2 | Amended and Restated Bylaws | 8-K | 001-38583 | 3.1 | 12/12/2023 | |
| 4.1 | Specimen Stock Certificate Evidencing the Shares of Common Stock | S-1/A | 333-225824 | 4.1 | 7/9/2018 | |
| 10.1 | Sales Agreement, dated June 21, 2024, by and among Crinetics Pharmaceuticals, Inc., Leerink Partners LLC and Cantor Fitzgerald & Co. | 8-K | 001-38583 | 1.1 | 6/21/2024 | |
| 31.1 | Certification of Chief Executive Officer pursuant to Rule 13(a)-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes Oxley Act of 2002 | X | ||||
| 31.2 | Certification of Chief Financial Officer pursuant to Rule 13(a)-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes Oxley Act of 2002 | X | ||||
| 32.1* | Certification of Chief Executive Officer and Chief Financial Officer pursuant 18. U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002 | X | ||||
| 101.INS | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the inline XBRL document | X | ||||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document. | X | ||||
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document. | X | ||||
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document. | X | ||||
| 101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document. | X | ||||
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | X | ||||
| 104 | Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101) | X | ||||
- The certification attached as Exhibit 32.1 that accompanies this Quarterly Report on Form 10-Q is not deemed filed with the SEC and is not to be incorporated by reference into any filing of Crinetics Pharmaceuticals, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Form 10-Q, irrespective of any general incorporation language contained in such filing.
SIGNAT URES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Crinetics Pharmaceuticals, Inc. | ||
| Date: August 8, 2024 | By: | /s/ R. Scott Struthers, Ph.D. |
|---|---|---|
| R. Scott Struthers, Ph.D. | ||
| President and Chief Executive Officer | ||
| (Principal executive officer) | ||
| Date: August 8, 2024 | By: | /s/ Marc J.S. Wilson |
| Marc J.S. Wilson | ||
| Chief Financial Officer | ||
| (Principal financial and accounting officer) | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.